Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
$1.51
+1.3%
$1.72
$0.99
$8.77
$75.61M2.71.67 million shs1.83 million shs
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$1.41
+5.7%
$1.69
$1.09
$7.67
$16.34M0.5350,110 shs73,082 shs
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
$19.68
$11.48
$19.75
$384.69M1.35129,776 shs8,375 shs
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
$23.01
$22.89
$3.11
$23.21
$389.61M2.111.52 million shsN/A
Prevail Therapeutics Inc. stock logo
PRVL
Prevail Therapeutics
$23.00
$23.01
$9.02
$23.35
$787.66M1.59955,800 shsN/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
+1.34%-3.21%-39.11%+33.63%-80.03%
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
+5.72%+5.64%-24.54%-30.82%-78.42%
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
0.00%0.00%0.00%0.00%0.00%
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.00%0.00%0.00%0.00%0.00%
Prevail Therapeutics Inc. stock logo
PRVL
Prevail Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
1.5233 of 5 stars
3.52.00.00.00.00.80.6
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
4.1033 of 5 stars
3.55.00.04.30.61.70.0
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
N/AN/AN/AN/AN/AN/AN/AN/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.6796 of 5 stars
0.00.00.04.70.02.50.0
Prevail Therapeutics Inc. stock logo
PRVL
Prevail Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
3.00
Buy$14.43855.53% Upside
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
3.00
Buy$4.00184.70% Upside
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
0.00
N/AN/AN/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.00
N/AN/AN/A
Prevail Therapeutics Inc. stock logo
PRVL
Prevail Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CBMG, HARP, PRVL, CABA, and CASI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
5/19/2025
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
5/16/2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$17.00 ➝ $13.00
5/15/2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$23.00 ➝ $25.00
4/9/2025
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $4.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/AN/AN/AN/A$3.12 per shareN/A
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$28.54M0.61N/AN/A$0.12 per share11.71
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
$340K0.00N/AN/A$2.89 per share0.00
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
$37.34M10.43N/AN/A$1.63 per share14.12
Prevail Therapeutics Inc. stock logo
PRVL
Prevail Therapeutics
N/AN/AN/AN/A$4.85 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
-$115.86M-$2.54N/AN/AN/AN/A-78.29%-65.68%8/6/2025 (Estimated)
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
-$39.26M-$2.55N/AN/A-129.05%-972.55%-77.33%8/15/2025 (Estimated)
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
-$49.98MN/AN/AN/AN/AN/A-144.80%-61.68%N/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
-$67.73M-$8.76N/AN/AN/A-81.68%-893.55%-45.98%N/A
Prevail Therapeutics Inc. stock logo
PRVL
Prevail Therapeutics
-$63.19M-$2.22N/AN/AN/AN/A-55.57%-48.14%N/A

Latest CBMG, HARP, PRVL, CABA, and CASI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q1 2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
-$0.67-$0.71-$0.04-$0.71N/AN/A
5/16/2025Q1 2025
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
-$0.61-$0.69-$0.08-$0.69$7.39 million$6.24 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/AN/AN/AN/AN/A
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
N/AN/AN/AN/AN/A
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
N/AN/AN/AN/AN/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
N/AN/AN/AN/AN/A
Prevail Therapeutics Inc. stock logo
PRVL
Prevail Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/A
3.96
3.96
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
N/A
0.81
0.68
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
N/A
0.47
0.47
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
N/A
1.89
1.89
Prevail Therapeutics Inc. stock logo
PRVL
Prevail Therapeutics
N/A
7.56
7.56
CompanyEmployeesShares OutstandingFree FloatOptionable
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
5050.74 million45.03 millionOptionable
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
18012.30 million9.69 millionOptionable
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
21719.48 millionN/AOptionable
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
5316.93 million14.05 millionOptionable
Prevail Therapeutics Inc. stock logo
PRVL
Prevail Therapeutics
6634.25 millionN/ANot Optionable

Recent News About These Companies

Prevail Bank donates to 29 charitable programs
Prevail Bank’s matching funds campaign garners more than $20K
Prevail receives $10,000 gift from Elements Cares
Prevail Bank launches Holiday Matching Funds campaign
Pasto Italiano goes Purple for Prevail

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cabaletta Bio stock logo

Cabaletta Bio NASDAQ:CABA

$1.51 +0.02 (+1.34%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$1.52 +0.01 (+0.66%)
As of 07/8/2025 06:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

CASI Pharmaceuticals stock logo

CASI Pharmaceuticals NASDAQ:CASI

$1.40 +0.08 (+5.72%)
As of 07/8/2025 03:59 PM Eastern

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Cellular Biomedicine Group stock logo

Cellular Biomedicine Group NASDAQ:CBMG

Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.

Harpoon Therapeutics stock logo

Harpoon Therapeutics NASDAQ:HARP

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

Prevail Therapeutics stock logo

Prevail Therapeutics NASDAQ:PRVL

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.